{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:03:44Z","timestamp":1793437424595,"version":"4.5.0"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001775","name":"University of Technology Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001775","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This review synthesises evidence published between 2020 and 2025 on emerging therapeutic strategies for asthma, with a focus on three interrelated domains: targeted treatments across asthma endotypes, advances in drug delivery aimed at improving pulmonary deposition and therapeutic efficiency, and technology-enabled tools to support adherence and disease management. We examine how biologics, regenerative and gene-based approaches, nanomedicine platforms, and digital health interventions are reshaping asthma care, while critically appraising their clinical maturity and implementation challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Advances in precision therapy have substantially improved outcomes for patients with severe asthma, particularly through biologics targeting IgE, IL-5 or its receptor, IL-4\/IL-13 signalling, and the upstream epithelial alarmin thymic stromal lymphopoietin. These agents consistently reduce exacerbation frequency and systemic corticosteroid use in selected populations, with favourable short- to medium-term safety profiles. In contrast, regenerative strategies such as mesenchymal stem cell\u2013based therapies, gene-based interventions including miRNA and siRNA modulation, and tolerogenic mRNA vaccines remain largely preclinical, offering mechanistic insight but limited clinical readiness. Nanoparticle-enabled drug delivery systems show potential to enhance pulmonary targeting and controlled release, though evidence is predominantly experimental. In parallel, smart inhalers, digital therapeutics, and environmental monitoring technologies address behavioural and environmental determinants of asthma control by improving adherence, inhaler technique, and trigger identification. However, their real-world impact is constrained by cost, integration into clinical workflows, and limited long-term effectiveness data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Asthma management is increasingly moving toward precision, endotype-informed care supported by targeted biologics, advanced delivery systems, and digital self-management tools. While biologics represent the most clinically established advances, regenerative, gene-based, and nanomedicine approaches remain exploratory and require robust long-term evaluation. Key priorities for future research include effective therapies for non\u2013Type 2 and steroid-resistant asthma, improved affordability and equitable access, and integrated care models that combine biomarkers with adherence and environmental monitoring to optimise sustained disease control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11882-026-01265-6","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:34:54Z","timestamp":1772786094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Emerging Therapeutic Strategies in Asthma: Advances in Treatment, Drug Delivery, Drug Adherence, and Disease Management"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7486-3485","authenticated-orcid":false,"given":"Ying Xuan","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8462-6827","authenticated-orcid":false,"given":"Yi Ning","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9459-631X","authenticated-orcid":false,"given":"Yuet Thong","family":"Looi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5074-1361","authenticated-orcid":false,"given":"Yap Wern","family":"Chuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9275-9686","authenticated-orcid":false,"given":"Kai Xin","family":"Chiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-9398","authenticated-orcid":false,"given":"Rebecca Shin-Yee","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-7678","authenticated-orcid":false,"given":"Nancy Choon-Si","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1006-3649","authenticated-orcid":false,"given":"Bey Hing","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"1265_CR1","doi-asserted-by":"publisher","unstructured":"Holgate ST, Thomas M, Asthma. Middleton\u2019s Allergy Essentials [Internet]. Elsevier; 2017 [cited 2025 Aug 27]. pp. 151\u2013204. https:\/\/doi.org\/10.1016\/B978-0-323-37579-5.00007-6","DOI":"10.1016\/B978-0-323-37579-5.00007-6"},{"key":"1265_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jaci.2024.02.011","volume":"153","author":"P Bradding","year":"2024","unstructured":"Bradding P, Porsbjerg C, C\u00f4t\u00e9 A, Dahl\u00e9n S-E, Hallstrand TS, Brightling CE. Airway hyperresponsiveness in asthma: the role of the epithelium. J Allergy Clin Immunol. 2024;153:1181\u201393. https:\/\/doi.org\/10.1016\/j.jaci.2024.02.011.","journal-title":"J Allergy Clin Immunol"},{"key":"1265_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101333","volume":"46","author":"T Boonpiyathad","year":"2019","unstructured":"Boonpiyathad T, S\u00f6zener ZC, Satitsuksanoa P, Akdis CA. Immunologic mechanisms in asthma. Semin Immunol. 2019;46:101333. https:\/\/doi.org\/10.1016\/j.smim.2019.101333.","journal-title":"Semin Immunol"},{"key":"1265_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2332\/allergolint.R-07-151","volume":"56","author":"K Yamauchi","year":"2007","unstructured":"Yamauchi K, Inoue H. Airway remodeling in asthma and irreversible airflow limitation - ECM deposition in airway and possible therapy for remodeling. Allergol Int. 2007;56:321\u20139. https:\/\/doi.org\/10.2332\/allergolint.R-07-151.","journal-title":"Allergol Int"},{"key":"1265_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00246","volume":"7","author":"SC Dharmage","year":"2019","unstructured":"Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:246. https:\/\/doi.org\/10.3389\/fped.2019.00246.","journal-title":"Front Pediatr"},{"key":"1265_CR6","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s12325-017-0520-0","volume":"34","author":"B Ding","year":"2017","unstructured":"Ding B, Small M. Disease burden of mild asthma: findings from a cross-sectional real-world survey. Adv Ther. 2017;34:1109\u201327. https:\/\/doi.org\/10.1007\/s12325-017-0520-0.","journal-title":"Adv Ther"},{"key":"1265_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106915","volume":"200","author":"M Cazzola","year":"2022","unstructured":"Cazzola M, Braido F, Calzetta L, Matera MG, Piraino A, Rogliani P, et al. The 5T approach in asthma: triple therapy targeting treatable traits. Respir Med. 2022;200:106915. https:\/\/doi.org\/10.1016\/j.rmed.2022.106915.","journal-title":"Respir Med"},{"key":"1265_CR8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240103","volume":"221","author":"MJ Schuijs","year":"2024","unstructured":"Schuijs MJ, Brenis Gomez CM, Bick F, Van Moorleghem J, Vanheerswynghels M, Van Loo G, et al. Interleukin-33\u2013activated basophils promote asthma by regulating Th2 cell entry into lung tissue. J Exp Med. 2024;221:e20240103. https:\/\/doi.org\/10.1084\/jem.20240103.","journal-title":"J Exp Med"},{"key":"1265_CR9","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/cea.14367","volume":"53","author":"M Belikova","year":"2023","unstructured":"Belikova M, S\u00e4fholm J, Al-Ameri M, Orre A, Dahl\u00e9n S, Adner M. Combined exposure to the alarmins TSLP, IL\u201033 and IL\u201025 enhances mast cell\u2010dependent contractions of human bronchi. Clin Exp Allergy. 2023;53:1062\u20136. https:\/\/doi.org\/10.1111\/cea.14367.","journal-title":"Clin Exp Allergy"},{"key":"1265_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111899","volume":"131","author":"H-F Lu","year":"2024","unstructured":"Lu H-F, Zhou Y-C, Luo D-D, Yang D-H, Wang X-J, Cheng B-H, et al. ILC2s: unraveling the innate immune orchestrators in allergic inflammation. Int Immunopharmacol. 2024;131:111899. https:\/\/doi.org\/10.1016\/j.intimp.2024.111899.","journal-title":"Int Immunopharmacol"},{"key":"1265_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jaci.2023.03.001","volume":"152","author":"M Hvidtfeldt","year":"2023","unstructured":"Hvidtfeldt M, Sverrild A, Pulga A, Fr\u00f8ssing L, Silberbrandt A, Hostrup M, et al. Airway hyperresponsiveness reflects corticosteroid-sensitive mast cell involvement across asthma phenotypes. J Allergy Clin Immunol. 2023;152:107\u2013116.e4. https:\/\/doi.org\/10.1016\/j.jaci.2023.03.001.","journal-title":"J Allergy Clin Immunol"},{"key":"1265_CR12","doi-asserted-by":"publisher","unstructured":"Dua K, Nammi S, Chang D, Chellappan DK, Gupta G, Collet T, editors. Medicinal Plants for Lung Diseases: A Pharmacological and Immunological Perspective [Internet]. Singapore: Springer Singapore; 2021 [cited 2025 Aug 27]. https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-981-33-6850-7. Accessed 27 Aug 2025.","DOI":"10.1007\/978-981-33-6850-7"},{"key":"1265_CR13","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jaci.2023.01.020","volume":"151","author":"AT Akenroye","year":"2023","unstructured":"Akenroye AT, Segal JB, Zhou G, Foer D, Li L, Alexander GC, et al. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: a target trial emulation. J Allergy Clin Immunol. 2023;151:1269\u201376. https:\/\/doi.org\/10.1016\/j.jaci.2023.01.020.","journal-title":"J Allergy Clin Immunol"},{"key":"1265_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","volume":"208","author":"J Corren","year":"2023","unstructured":"Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208:13\u201324. https:\/\/doi.org\/10.1164\/rccm.202210-2005OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1265_CR15","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1016\/j.jaip.2023.07.024","volume":"11","author":"MC Liu","year":"2023","unstructured":"Liu MC, Bagnasco D, Matucci A, Pilette C, Price RG, Maxwell AC, et al. Mepolizumab in patients with severe asthma and comorbidities: 1-year REALITI-A analysis. J Allergy Clin Immunol Pract. 2023;11:3650\u20133661.e3. https:\/\/doi.org\/10.1016\/j.jaip.2023.07.024.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1265_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/jpids\/piae093.049","volume":"13","author":"W Ahmed","year":"2024","unstructured":"Ahmed W, Shidid S, Amornruk N, Abdelmajid H, Norowitz YM, Kohlhoff S, et al. Th2 and IL-17 responses in Chlamydia pneumoniae-stimulated PBMC in asthmatic and non-asthmatic subjects. J Pediatr Infect Dis Soc. 2024;13:18\u201318. https:\/\/doi.org\/10.1093\/jpids\/piae093.049.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"1265_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2021.676930","volume":"2","author":"N Turan","year":"2021","unstructured":"Turan N, Van Der Veen TA, Draijer C, Fattahi F, Ten Hacken NH, Timens W, et al. Neutrophilic asthma is associated with smoking, high numbers of IRF5+, and low numbers of IL10\u2009+\u2009macrophages. Front Allergy. 2021;2:676930. https:\/\/doi.org\/10.3389\/falgy.2021.676930.","journal-title":"Front Allergy"},{"key":"1265_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2023.131787","volume":"457","author":"C Lu","year":"2023","unstructured":"Lu C, Wang F, Liu Q, Deng M, Yang X, Ma P. Effect of NO2 exposure on airway inflammation and oxidative stress in asthmatic mice. J Hazard Mater. 2023;457:131787. https:\/\/doi.org\/10.1016\/j.jhazmat.2023.131787.","journal-title":"J Hazard Mater"},{"key":"1265_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.vetimm.2008.10.293","volume":"128","author":"J Harris","year":"2009","unstructured":"Harris J, Master SS, De Haro SA, Delgado M, Roberts EA, Hope JC, et al. Th1\u2013Th2 polarisation and autophagy in the control of intracellular mycobacteria by macrophages. Vet Immunol Immunopathol. 2009;128:37\u201343. https:\/\/doi.org\/10.1016\/j.vetimm.2008.10.293.","journal-title":"Vet Immunol Immunopathol"},{"key":"1265_CR20","doi-asserted-by":"publisher","unstructured":"Vermeersch G, Proost P, Struyf S, Gouwy M, Devos T. CXCL8 and its cognate receptors CXCR1\/CXCR2 in primary myelofibrosis. haematol [Internet]. 2024 [cited 2025 Aug 26]; https:\/\/doi.org\/10.3324\/haematol.2023.284921","DOI":"10.3324\/haematol.2023.284921"},{"key":"1265_CR21","doi-asserted-by":"publisher","first-page":"9583","DOI":"10.1007\/s00210-025-03970-x","volume":"398","author":"MS Hussain","year":"2025","unstructured":"Hussain MS, Goyal A, Goyal K, Nellore SRJ, Shahwan J. Targeting CXCR2 signaling in inflammatory lung diseases: neutrophil-driven inflammation and emerging therapies. Naunyn-Schmiedebergs Arch Pharmacol. 2025;398:9583\u2013607. https:\/\/doi.org\/10.1007\/s00210-025-03970-x.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"1265_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/imm.13423","volume":"165","author":"A Singhal","year":"2022","unstructured":"Singhal A, Kumar S. Neutrophil and remnant clearance in immunity and inflammation. Immunology. 2022;165:22\u201343. https:\/\/doi.org\/10.1111\/imm.13423.","journal-title":"Immunology"},{"key":"1265_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/20406223221097327","volume":"13","author":"B Ragnoli","year":"2022","unstructured":"Ragnoli B, Morjaria J, Pignatti P, Montuschi P, Barbieri M, Mondini L, et al. Dupilumab and tezepelumab in severe refractory asthma: new opportunities. Ther Adv Chronic Dis. 2022;13:20406223221097327. https:\/\/doi.org\/10.1177\/20406223221097327.","journal-title":"Ther Adv Chronic Dis"},{"key":"1265_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001549","volume":"10","author":"W Wang","year":"2023","unstructured":"Wang W, Li J, Zou C, Zhao L, Zhu Y, Guo Y, et al. Omalizumab for Chinese patients with moderate-to-severe allergic asthma in real-world clinical setting: a prospective, observational study. BMJ Open Respir Res. 2023;10:e001549. https:\/\/doi.org\/10.1136\/bmjresp-2022-001549.","journal-title":"BMJ Open Respir Res"},{"key":"1265_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-022-02246-x","volume":"22","author":"CA Torres-Duque","year":"2022","unstructured":"Torres-Duque CA, Ocampo-G\u00f3mez J, Castillo MM, Cano-Rosales D, Giraldo-Montoya \u00c1, Rodr\u00edguez F, et al. Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia. BMC Pulm Med. 2022;22:447. https:\/\/doi.org\/10.1186\/s12890-022-02246-x.","journal-title":"BMC Pulm Med"},{"key":"1265_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/17534666231170821","volume":"17","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Li C, Wan J, Zhang M, Nong Y, Lin J. Role of clinical biomarkers in predicting the effectiveness of omalizumab. Ther Adv Respir Dis. 2023;17:17534666231170821. https:\/\/doi.org\/10.1177\/17534666231170821.","journal-title":"Ther Adv Respir Dis"},{"key":"1265_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/14799731231159673","volume":"20","author":"L Rogers","year":"2023","unstructured":"Rogers L, Holweg CT, Pazwash H, Ko J, Louie S. Age of asthma onset does not impact the response to omalizumab. Chron Respir Dis. 2023;20:14799731231159673. https:\/\/doi.org\/10.1177\/14799731231159673.","journal-title":"Chron Respir Dis"},{"key":"1265_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.anai.2021.01.015","volume":"126","author":"M Chen","year":"2021","unstructured":"Chen M, Choo E, Yoo B, Raut P, Haselkorn T, Pazwash H, et al. No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities. Ann Allergy Asthma Immunol. 2021;126:666\u201373. https:\/\/doi.org\/10.1016\/j.anai.2021.01.015.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1265_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106228","volume":"100","author":"W Phipatanakul","year":"2021","unstructured":"Phipatanakul W, Mauger DT, Guilbert TW, Bacharier LB, Durrani S, Jackson DJ, et al. Preventing asthma in high risk kids (PARK) with omalizumab: design, rationale, methods, lessons learned and adaptation. Contemp Clin Trials. 2021;100:106228. https:\/\/doi.org\/10.1016\/j.cct.2020.106228.","journal-title":"Contemp Clin Trials"},{"key":"1265_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70264","volume":"18","author":"Z Shen","year":"2025","unstructured":"Shen Z, Jin T, Wu K, Zhao J, Jiang Q, Guo T, et al. Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity profiles of a single-dose JYB1904 in healthy Chinese participants: a phase Ia, randomized, double\u2010blind, placebo\u2010controlled study. Clin Transl Sci. 2025;18:e70264. https:\/\/doi.org\/10.1111\/cts.70264.","journal-title":"Clin Transl Sci"},{"key":"1265_CR31","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jaci.2024.07.020","volume":"154","author":"I Howell","year":"2024","unstructured":"Howell I, Yang F, Brown V, Cane J, Marchi E, Azim A, et al. Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma. J Allergy Clin Immunol. 2024;154:1146\u201358. https:\/\/doi.org\/10.1016\/j.jaci.2024.07.020.","journal-title":"J Allergy Clin Immunol"},{"key":"1265_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaci.2024.10.024","volume":"155","author":"K Domvri","year":"2025","unstructured":"Domvri K, Tsiouprou I, Bakakos P, Steiropoulos P, Katsoulis K, Kostikas K, et al. Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2025;155:425\u201335. https:\/\/doi.org\/10.1016\/j.jaci.2024.10.024.","journal-title":"J Allergy Clin Immunol"},{"key":"1265_CR33","doi-asserted-by":"publisher","DOI":"10.1177\/17534666241308406","volume":"19","author":"S-L Cheng","year":"2025","unstructured":"Cheng S-L, Lin S-M, Peng C-K, Chan M-C, Shen S-Y, Kuo P-H, et al. A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT). Ther Adv Respir Dis. 2025;19:17534666241308406. https:\/\/doi.org\/10.1177\/17534666241308406.","journal-title":"Ther Adv Respir Dis"},{"key":"1265_CR34","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","volume":"10","author":"C Pilette","year":"2022","unstructured":"Pilette C, Canonica GW, Chaudhuri R, Chupp G, Lee FE-H, Lee JK, et al. REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma. J Allergy Clin Immunology: Pract. 2022;10:2646\u201356. https:\/\/doi.org\/10.1016\/j.jaip.2022.05.042.","journal-title":"J Allergy Clin Immunology: Pract"},{"key":"1265_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106260","volume":"176","author":"AS Bjerrum","year":"2021","unstructured":"Bjerrum AS, Skjold T, Schmid JM. Oral corticosteroid sparing effects of anti-IL5\/ anti-IL5 receptor treatment after 2 years of treatment. Respir Med. 2021;176:106260. https:\/\/doi.org\/10.1016\/j.rmed.2020.106260.","journal-title":"Respir Med"},{"key":"1265_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-021-01785-z","volume":"21","author":"E Mart\u00ednez-Morag\u00f3n","year":"2021","unstructured":"Mart\u00ednez-Morag\u00f3n E, Garc\u00eda-Moguel I, Nuevo J, Resler G, ORBE study investigators, Ant\u00e9para I, et al. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study). BMC Pulm Med. 2021;21:417. https:\/\/doi.org\/10.1186\/s12890-021-01785-z.","journal-title":"BMC Pulm Med"},{"key":"1265_CR37","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1016\/j.jaip.2024.04.026","volume":"12","author":"X Li","year":"2024","unstructured":"Li X, Newbold P, Katial R, Hirsch I, Li H, Martin UJ, et al. Multivariate cluster analyses to characterize asthma heterogeneity and benralizumab responsiveness. J Allergy Clin Immunol Pract. 2024;12:2732\u201343. https:\/\/doi.org\/10.1016\/j.jaip.2024.04.026.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1265_CR38","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","volume":"403","author":"DJ Jackson","year":"2024","unstructured":"Jackson DJ, Heaney LG, Humbert M, Kent BD, Shavit A, Hiljemark L, et al. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2024;403:271\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(23)02284-5.","journal-title":"Lancet"},{"key":"1265_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-01952-8","volume":"23","author":"F Menzella","year":"2022","unstructured":"Menzella F, Bargagli E, Aliani M, Bracciale P, Brussino L, Caiaffa MF, et al. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study. Respir Res. 2022;23:36. https:\/\/doi.org\/10.1186\/s12931-022-01952-8.","journal-title":"Respir Res"},{"key":"1265_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/DDDT.S392155","volume":"17","author":"TT Cheung","year":"2023","unstructured":"Cheung TT, Mai TH, Chia YL, Yap DY, Lee C-H, Chen CC-K, et al. Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants. DDDT. 2023;17:209\u201318. https:\/\/doi.org\/10.2147\/DDDT.S392155.","journal-title":"DDDT"},{"key":"1265_CR41","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jaip.2024.11.014","volume":"13","author":"DJ Jackson","year":"2025","unstructured":"Jackson DJ, Hamelmann E, Roberts G, Bacharier LB, Xia C, Gall R, et al. Dupilumab efficacy and safety in children with moderate to severe asthma and high blood eosinophils: a post hoc analysis of VOYAGE. J Allergy Clin Immunol Pract. 2025;13:568\u201375. https:\/\/doi.org\/10.1016\/j.jaip.2024.11.014.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1265_CR42","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1016\/j.jaip.2024.08.038","volume":"12","author":"JF Maspero","year":"2024","unstructured":"Maspero JF, Antila MA, Deschildre A, Bacharier LB, Altincatal A, Laws E, et al. Dupilumab efficacy in children with type 2 asthma receiving high- to medium-dose inhaled corticosteroids (VOYAGE). J Allergy Clin Immunol Pract. 2024;12:3303\u201312. https:\/\/doi.org\/10.1016\/j.jaip.2024.08.038.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1265_CR43","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.alit.2024.02.002","volume":"73","author":"T Tajiri","year":"2024","unstructured":"Tajiri T, Suzuki M, Nishiyama H, Ozawa Y, Kurokawa R, Takeda N, et al. Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: a prospective, observational study. Allergol Int. 2024;73:406\u201315. https:\/\/doi.org\/10.1016\/j.alit.2024.02.002.","journal-title":"Allergol Int"},{"key":"1265_CR44","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.anai.2022.10.018","volume":"130","author":"NA Hanania","year":"2023","unstructured":"Hanania NA, Castro M, Bateman E, Pavord ID, Papi A, FitzGerald JM, et al. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction. Ann Allergy Asthma Immunol. 2023;130:206\u2013214.e2. https:\/\/doi.org\/10.1016\/j.anai.2022.10.018.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1265_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.chest.2022.01.071","volume":"162","author":"LD Sher","year":"2022","unstructured":"Sher LD, Wechsler ME, Rabe KF, Maspero JF, Daizadeh N, Mao X, et al. Dupilumab reduces oral corticosteroid use in patients with corticosteroid-dependent severe asthma. Chest. 2022;162:46\u201355. https:\/\/doi.org\/10.1016\/j.chest.2022.01.071.","journal-title":"Chest"},{"key":"1265_CR46","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jaip.2022.03.020","volume":"10","author":"C Domingo","year":"2022","unstructured":"Domingo C, Maspero JF, Castro M, Hanania NA, Ford LB, Halpin DMG, et al. Dupilumab efficacy in steroid-dependent severe asthma by baseline oral corticosteroid dose. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10:1835\u201343. https:\/\/doi.org\/10.1016\/j.jaip.2022.03.020.","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"key":"1265_CR47","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.alit.2020.04.002","volume":"69","author":"Y Tohda","year":"2020","unstructured":"Tohda Y, Nakamura Y, Fujisawa T, Ebisawa M, Arima K, Miyata M, et al. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study. Allergol Int. 2020;69:578\u201387. https:\/\/doi.org\/10.1016\/j.alit.2020.04.002.","journal-title":"Allergol Int"},{"key":"1265_CR48","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.jaci.2024.07.029","volume":"154","author":"E Bleecker","year":"2024","unstructured":"Bleecker E, Blaiss M, Jacob-Nara J, Huynh L, Duh MS, Guo T, et al. Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: real-world US ADVANTAGE study. J Allergy Clin Immunol. 2024;154:1500\u201310. https:\/\/doi.org\/10.1016\/j.jaci.2024.07.029.","journal-title":"J Allergy Clin Immunol"},{"key":"1265_CR49","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.anai.2023.05.028","volume":"131","author":"A Menzies-Gow","year":"2023","unstructured":"Menzies-Gow A, Bourdin A, Chupp G, Israel E, Hellqvist \u00c5, Hunter G, et al. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2023;131:343\u2013348.e2. https:\/\/doi.org\/10.1016\/j.anai.2023.05.028.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1265_CR50","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/cpdd.775","volume":"9","author":"K Sakamoto","year":"2020","unstructured":"Sakamoto K, Matsuki S, Irie S, Uchida N, Hayashi N, Horiuchi M, et al. A phase 1, randomized, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tezepelumab in healthy Japanese men. Clinical Pharm in Drug Dev. 2020;9:833\u201340. https:\/\/doi.org\/10.1002\/cpdd.775.","journal-title":"Clinical Pharm in Drug Dev"},{"key":"1265_CR51","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/all.15197","volume":"77","author":"J Corren","year":"2022","unstructured":"Corren J, Pham T, Garcia Gil E, Sa\u0142apa K, Ren P, Parnes JR, et al. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy. 2022;77:1786\u201396. https:\/\/doi.org\/10.1111\/all.15197.","journal-title":"Allergy"},{"key":"1265_CR52","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.anai.2021.08.008","volume":"127","author":"T-H Pham","year":"2021","unstructured":"Pham T-H, Chen C, Colice G, Parnes JR, Griffiths JM, Cook B. Tezepelumab normalizes serum interleukin-5 and \u2013 13 levels in patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2021;127:689\u201391. https:\/\/doi.org\/10.1016\/j.anai.2021.08.008.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1265_CR53","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.anai.2023.08.015","volume":"131","author":"ID Pavord","year":"2023","unstructured":"Pavord ID, Hoyte FCL, Lindsley AW, Ambrose CS, Spahn JD, Roseti SL, et al. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR). Ann Allergy Asthma Immunol. 2023;131:587\u2013597.e3. https:\/\/doi.org\/10.1016\/j.anai.2023.08.015.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1265_CR54","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.alit.2022.07.004","volume":"72","author":"T Ishizuka","year":"2023","unstructured":"Ishizuka T, Menzies-Gow A, Okada H, Fukushima Y, Hayashi N, Colice G, et al. Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study. Allergol Int. 2023;72:82\u20138. https:\/\/doi.org\/10.1016\/j.alit.2022.07.004.","journal-title":"Allergol Int"},{"key":"1265_CR55","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1080\/02770903.2022.2082309","volume":"60","author":"M Shinkai","year":"2023","unstructured":"Shinkai M, Ebisawa M, Fukushima Y, Takeuchi S, Okada H, Tokiyo T, et al. One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study. J Asthma. 2023;60:616\u201324. https:\/\/doi.org\/10.1080\/02770903.2022.2082309.","journal-title":"J Asthma"},{"key":"1265_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.intimp.2014.06.011","volume":"22","author":"I Ogulur","year":"2014","unstructured":"Ogulur I, Gurhan G, Kombak FE, Filinte D, Barlan I, Akkoc T. Allogeneic pluripotent stem cells suppress airway inflammation in murine model of acute asthma. Int Immunopharmacol. 2014;22:31\u201340. https:\/\/doi.org\/10.1016\/j.intimp.2014.06.011.","journal-title":"Int Immunopharmacol"},{"key":"1265_CR57","doi-asserted-by":"publisher","first-page":"6957","DOI":"10.1016\/j.sjbs.2021.07.071","volume":"28","author":"M Huang","year":"2021","unstructured":"Huang M, Mehrabi Nasab E, Athari SS. Immunoregulatory effect of mesenchymal stem cell via mitochondria signaling pathways in allergic asthma. Saudi J Biol Sci. 2021;28:6957\u201362. https:\/\/doi.org\/10.1016\/j.sjbs.2021.07.071.","journal-title":"Saudi J Biol Sci"},{"key":"1265_CR58","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","volume":"50","author":"BN Lambrecht","year":"2019","unstructured":"Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity. 2019;50:975\u201391. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.018.","journal-title":"Immunity"},{"key":"1265_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27694","volume":"10","author":"OA Mohammed","year":"2024","unstructured":"Mohammed OA, Doghish AS, Alamri MMS, Alharthi MH, Alfaifi J, Adam MIE, et al. The role of matrix metalloproteinase-2 and miR-196a2 in bronchial asthma pathogenesis and diagnosis. Heliyon. 2024;10:e27694. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27694.","journal-title":"Heliyon"},{"key":"1265_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/3057624","volume":"2018","author":"M Wang","year":"2018","unstructured":"Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: properties and clinical application. Stem Cells Int. 2018;2018:1\u201312. https:\/\/doi.org\/10.1155\/2018\/3057624.","journal-title":"Stem Cells Int"},{"key":"1265_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111713","volume":"130","author":"W Kun","year":"2024","unstructured":"Kun W, Xiaomei C, Lei Y, Huizhi Z. Modulating Th1\/Th2 drift in asthma-related immune inflammation by enhancing bone mesenchymal stem cell homing through targeted inhibition of the Notch1\/Jagged1 signaling pathway. Int Immunopharmacol. 2024;130:111713. https:\/\/doi.org\/10.1016\/j.intimp.2024.111713.","journal-title":"Int Immunopharmacol"},{"key":"1265_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.snb.2024.136031","volume":"416","author":"C-H Sun","year":"2024","unstructured":"Sun C-H, Lee K-Y, Chan Y-F, Ho S-C, Liu C-Y, Wu S-M, et al. A bronchiole-on-a-chip and a stretching system for studying human disease model of asthma attack. Sens Actuators B Chem. 2024;416:136031. https:\/\/doi.org\/10.1016\/j.snb.2024.136031.","journal-title":"Sens Actuators B Chem"},{"key":"1265_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.853848","volume":"13","author":"Z Wang","year":"2022","unstructured":"Wang Z, Song Y, Jiang J, Piao Y, Li L, Bai Q, et al. MicroRNA-182-5p attenuates asthmatic airway inflammation by targeting NOX4. Front Immunol. 2022;13:853848. https:\/\/doi.org\/10.3389\/fimmu.2022.853848.","journal-title":"Front Immunol"},{"key":"1265_CR64","doi-asserted-by":"publisher","first-page":"201","DOI":"10.14715\/cmb\/2023.69.9.31","volume":"69","author":"A Xuan","year":"2023","unstructured":"Xuan A, Yang M, Xia Q, Sun Q. Downregulation of NOX4 improves airway remodeling and inflammation by the TGF-\u03b21-Smad2\/3 pathway in asthma. Cell Mol Biol (Noisy-le-grand). 2023;69:201\u20136. https:\/\/doi.org\/10.14715\/cmb\/2023.69.9.31.","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"1265_CR65","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jconrel.2022.10.020","volume":"352","author":"M Zhang","year":"2022","unstructured":"Zhang M, Jiang H, Wu L, Lu H, Bera H, Zhao X, et al. Airway epithelial cell-specific delivery of lipid nanoparticles loading siRNA for asthma treatment. J Control Release. 2022;352:422\u201337. https:\/\/doi.org\/10.1016\/j.jconrel.2022.10.020.","journal-title":"J Control Release"},{"key":"1265_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412543","volume":"12","author":"F Wang","year":"2025","unstructured":"Wang F, Lou J, Lou X, Wu F, Gao X, Yao X, et al. A spleen-targeted tolerogenic mRNA\u2010LNPs vaccine for the treatment of experimental asthma. Adv Sci. 2025;12:2412543. https:\/\/doi.org\/10.1002\/advs.202412543.","journal-title":"Adv Sci"},{"key":"1265_CR67","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jconrel.2024.01.044","volume":"367","author":"Y Yu","year":"2024","unstructured":"Yu Y, Ni M, Zheng Y, Huang Y. Airway epithelial-targeted nanoparticle reverses asthma in inhalation therapy. J Control Release. 2024;367:223\u201334. https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.044.","journal-title":"J Control Release"},{"key":"1265_CR68","doi-asserted-by":"publisher","DOI":"10.18502\/ijaai.v21i1.8617","author":"L Chen","year":"2022","unstructured":"Chen L, Mehrabi Nasab E, Shamsadin Athari S. Effect of loaded Glycyrrhizic acid on PLGA nano-particle on treatment of allergic asthma. Iran J Allergy Asthma Immunol. 2022. https:\/\/doi.org\/10.18502\/ijaai.v21i1.8617.","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"1265_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.724525","volume":"12","author":"H Jin","year":"2021","unstructured":"Jin H, Li J, Zhang M, Luo R, Lu P, Zhang W, et al. Berberine-loaded biomimetic nanoparticles attenuate inflammation of experimental allergic asthma via enhancing IL-12 expression. Front Pharmacol. 2021;12:724525. https:\/\/doi.org\/10.3389\/fphar.2021.724525.","journal-title":"Front Pharmacol"},{"key":"1265_CR70","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1016\/j.sjbs.2021.04.009","volume":"28","author":"D Wang","year":"2021","unstructured":"Wang D, Mehrabi Nasab E, Athari SS. Study effect of Baicalein encapsulated\/loaded Chitosan-nanoparticle on allergic asthma pathology in mouse model. Saudi J Biol Sci. 2021;28:4311\u20137. https:\/\/doi.org\/10.1016\/j.sjbs.2021.04.009.","journal-title":"Saudi J Biol Sci"},{"key":"1265_CR71","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1049\/mna2.12078","volume":"16","author":"H Li","year":"2021","unstructured":"Li H, Yao Y, Fu H. Novel pediatric suspension of nanoparticulate zafirlukast for the treatment of asthma: assessment and evaluation in animal model. Micro & Nano Letters. 2021;16:485\u201391. https:\/\/doi.org\/10.1049\/mna2.12078.","journal-title":"Micro & Nano Letters"},{"key":"1265_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106642","volume":"193","author":"A Pareek","year":"2024","unstructured":"Pareek A, Kothari R, Pareek A, Ratan Y, Kashania P, Jain V, et al. Development of a new inhaled swellable microsphere system for the dual delivery of naringenin-loaded solid lipid nanoparticles and doxofylline for the treatment of asthma. Eur J Pharm Sci. 2024;193:106642. https:\/\/doi.org\/10.1016\/j.ejps.2023.106642.","journal-title":"Eur J Pharm Sci"},{"key":"1265_CR73","doi-asserted-by":"publisher","first-page":"8635","DOI":"10.1080\/21655979.2021.1988364","volume":"12","author":"C Lv","year":"2021","unstructured":"Lv C, Li H, Cui H, Bi Q, Wang M. Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway. Bioengineered. 2021;12:8635\u201349. https:\/\/doi.org\/10.1080\/21655979.2021.1988364.","journal-title":"Bioengineered"},{"key":"1265_CR74","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaci.2011.09.011","volume":"128","author":"LK Williams","year":"2011","unstructured":"Williams LK, Peterson EL, Wells K, Ahmedani BK, Kumar R, Burchard EG, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128:1185\u20131191.e2. https:\/\/doi.org\/10.1016\/j.jaci.2011.09.011.","journal-title":"J Allergy Clin Immunol"},{"key":"1265_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016688","volume":"7","author":"HK Reddel","year":"2017","unstructured":"Reddel HK, Ampon RD, Sawyer SM, Peters MJ. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open. 2017;7:e016688. https:\/\/doi.org\/10.1136\/bmjopen-2017-016688.","journal-title":"BMJ Open"},{"key":"1265_CR76","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s41030-021-00167-4","volume":"7","author":"AHY Chan","year":"2021","unstructured":"Chan AHY, Pleasants RA, Dhand R, Tilley SL, Schworer SA, Costello RW, et al. Digital inhalers for asthma or chronic obstructive pulmonary disease: a scientific perspective. Pulm Ther. 2021;7:345\u201376. https:\/\/doi.org\/10.1007\/s41030-021-00167-4.","journal-title":"Pulm Ther"},{"key":"1265_CR77","doi-asserted-by":"publisher","unstructured":"Rakesh Margam. Smart inhalers: Harnessing IoT for precise asthma management. ierj [Internet]. 2024 [cited 2025 Aug 26];10. https:\/\/doi.org\/10.21276\/IERJ24265450564586","DOI":"10.21276\/IERJ24265450564586"},{"key":"1265_CR78","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3390\/s22031238","volume":"22","author":"M Kaloumenou","year":"2022","unstructured":"Kaloumenou M, Skotadis E, Lagopati N, Efstathopoulos E, Tsoukalas D. Breath Analysis: A Promising Tool for Disease Diagnosis\u2014The Role of Sensors. Sensors. 2022;22:1238. https:\/\/doi.org\/10.3390\/s22031238.","journal-title":"Sensors"},{"key":"1265_CR79","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/asi7050078","volume":"7","author":"H Almuhanna","year":"2024","unstructured":"Almuhanna H, Alenezi M, Abualhasan M, Alajmi S, Alfadhli R, Karar AS. AI Asthma Guard: Predictive Wearable Technology for Asthma Management in Vulnerable Populations. ASI. 2024;7:78. https:\/\/doi.org\/10.3390\/asi7050078.","journal-title":"ASI"},{"key":"1265_CR80","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.21037\/jtd-22-1492","volume":"15","author":"J-S Shim","year":"2023","unstructured":"Shim J-S, Kim B-K, Kim S-H, Kwon J-W, Ahn K-M, Kang S-Y, et al. A smartphone-based application for cough counting in patients with acute asthma exacerbation. J Thorac Dis. 2023;15:4053\u201365. https:\/\/doi.org\/10.21037\/jtd-22-1492.","journal-title":"J Thorac Dis"},{"key":"1265_CR81","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S2213-2600(15)00008-9","volume":"3","author":"AHY Chan","year":"2015","unstructured":"Chan AHY, Stewart AW, Harrison J, Camargo CA, Black PN, Mitchell EA. The effect of an electronic monitoring device with audiovisual reminder function on adherence to inhaled corticosteroids and school attendance in children with asthma: a randomised controlled trial. Lancet Respir Med. 2015;3:210\u20139. https:\/\/doi.org\/10.1016\/S2213-2600(15)00008-9.","journal-title":"Lancet Respir Med"},{"key":"1265_CR82","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1016\/j.jaip.2023.06.051","volume":"11","author":"SJ Van De Hei","year":"2023","unstructured":"Van De Hei SJ, Kim CH, Honkoop PJ, Sont JK, Schermer TRJ, MacHale E, et al. Long-Term Cost-Effectiveness of Digital Inhaler Adherence Technologies in Difficult-to-Treat Asthma. J Allergy Clin Immunology: Pract. 2023;11:3064\u2013e307315. https:\/\/doi.org\/10.1016\/j.jaip.2023.06.051.","journal-title":"J Allergy Clin Immunology: Pract"},{"key":"1265_CR83","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41533-023-00343-w","volume":"33","author":"SJ Van De Hei","year":"2023","unstructured":"Van De Hei SJ, Stoker N, Flokstra-de Blok BMJ, Poot CC, Meijer E, Postma MJ, et al. Anticipated barriers and facilitators for implementing smart inhalers in asthma medication adherence management. npj Prim Care Respir Med. 2023;33:22. https:\/\/doi.org\/10.1038\/s41533-023-00343-w.","journal-title":"npj Prim Care Respir Med"},{"key":"1265_CR84","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1186\/s13063-020-04694-4","volume":"21","author":"ET Sportel","year":"2020","unstructured":"Sportel ET, Oude Wolcherink MJ, Van Der Palen J, Lenferink A, Thio BJ, Movig KLL, et al. Does immediate smart feedback on therapy adherence and inhalation technique improve asthma control in children with uncontrolled asthma? A study protocol of the IMAGINE I study. Trials. 2020;21:801. https:\/\/doi.org\/10.1186\/s13063-020-04694-4.","journal-title":"Trials"},{"key":"1265_CR85","unstructured":"National Institute for Health and Care Excellence (NICE). Evidence reviews for smart inhalers: Asthma: diagnosis, monitoring and chronic asthma management (update): Evidence review R. 2024."},{"key":"1265_CR86","doi-asserted-by":"publisher","first-page":"e001400","DOI":"10.1136\/bmjresp-2022-001400","volume":"9","author":"SJ Van De Hei","year":"2022","unstructured":"Van De Hei SJ, Poot CC, Van Den Berg LN, Meijer E, Van Boven JFM, Flokstra-de Blok BMJ, et al. Effectiveness, usability and acceptability of a smart inhaler programme in patients with asthma: protocol of the multicentre, pragmatic, open-label, cluster randomised controlled acceptance trial. BMJ Open Resp Res. 2022;9:e001400. https:\/\/doi.org\/10.1136\/bmjresp-2022-001400.","journal-title":"BMJ Open Resp Res"},{"key":"1265_CR87","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.2147\/JMDH.S435492","volume":"16","author":"M Alotaibi","year":"2023","unstructured":"Alotaibi M, Alnajjar F, Alsayed BA, Alhmiedat T, Marei AM, Bushnag A, et al. An Observational Pilot Study of a Tailored Environmental Monitoring and Alert System for Improved Management of Chronic Respiratory Diseases. JMDH. 2023;16:3799\u2013811. https:\/\/doi.org\/10.2147\/JMDH.S435492.","journal-title":"JMDH"},{"key":"1265_CR88","doi-asserted-by":"publisher","DOI":"10.2196\/60147","volume":"8","author":"B Polivka","year":"2024","unstructured":"Polivka B, Krueger K, Bimbi O, Huntington-Moskos L, Nyenhuis S, Cramer E, et al. Integrating real-time air quality monitoring, ecological momentary assessment, and spirometry to evaluate asthma symptoms: usability study. JMIR Form Res. 2024;8:e60147. https:\/\/doi.org\/10.2196\/60147.","journal-title":"JMIR Form Res"},{"key":"1265_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s40733-021-00079-9","volume":"7","author":"S Xie","year":"2021","unstructured":"Xie S, Meeker JR, Perez L, Eriksen W, Localio A, Park H, et al. Feasibility and acceptability of monitoring personal air pollution exposure with sensors for asthma self-management. Asthma Res Pract. 2021;7:13. https:\/\/doi.org\/10.1186\/s40733-021-00079-9.","journal-title":"Asthma Res Pract"},{"key":"1265_CR90","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00408-017-9987-3","volume":"195","author":"S Dragonieri","year":"2017","unstructured":"Dragonieri S, Pennazza G, Carratu P, Resta O. Electronic nose technology in respiratory diseases. Lung. 2017;195:157\u201365. https:\/\/doi.org\/10.1007\/s00408-017-9987-3.","journal-title":"Lung"},{"key":"1265_CR91","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jaci.2018.10.058","volume":"143","author":"P Brinkman","year":"2019","unstructured":"Brinkman P, Wagener AH, Hekking P-P, Bansal AT, Maitland-van Der Zee A-H, Wang Y, et al. Identification and prospective stability of electronic nose (eNose)\u2013derived inflammatory phenotypes in patients with severe asthma. J Allergy Clin Immunol. 2019;143:1811\u2013e18207. https:\/\/doi.org\/10.1016\/j.jaci.2018.10.058.","journal-title":"J Allergy Clin Immunol"},{"key":"1265_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12111853","volume":"12","author":"P Bakakos","year":"2022","unstructured":"Bakakos P. Asthma: from phenotypes to personalized medicine. JPM. 2022;12:1853. https:\/\/doi.org\/10.3390\/jpm12111853.","journal-title":"JPM"},{"key":"1265_CR93","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/all.15601","volume":"78","author":"CJ Aranda","year":"2023","unstructured":"Aranda CJ, Gonzalez-Kozlova E, Saunders SP, Fernandes\u2010Braga W, Ota M, Narayanan S, et al. IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseases. Allergy. 2023;78:752\u201366. https:\/\/doi.org\/10.1111\/all.15601.","journal-title":"Allergy"},{"key":"1265_CR94","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jaip.2019.11.008","volume":"8","author":"N Akar-Ghibril","year":"2020","unstructured":"Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8:429\u201340. https:\/\/doi.org\/10.1016\/j.jaip.2019.11.008.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1265_CR95","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.mucimm.2023.07.002","volume":"16","author":"B Curren","year":"2023","unstructured":"Curren B, Ahmed T, Howard DR, Md AU, Sebina I, Rashid RB, et al. IL-33-induced neutrophilic inflammation and NETosis underlie rhinovirus-triggered exacerbations of asthma. Mucosal Immunol. 2023;16:671\u201384. https:\/\/doi.org\/10.1016\/j.mucimm.2023.07.002.","journal-title":"Mucosal Immunol"},{"key":"1265_CR96","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jaci.2021.09.013","volume":"149","author":"V Pivniouk","year":"2022","unstructured":"Pivniouk V, Gimenes-Junior JA, Ezeh P, Michael A, Pivniouk O, Hahn S, et al. Airway administration of OM-85, a bacterial lysate, blocks experimental asthma by targeting dendritic cells and the epithelium\/IL-33\/ILC2 axis. J Allergy Clin Immunol. 2022;149:943\u201356. https:\/\/doi.org\/10.1016\/j.jaci.2021.09.013.","journal-title":"J Allergy Clin Immunol"},{"key":"1265_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31491-1","volume":"13","author":"J Ham","year":"2022","unstructured":"Ham J, Kim J, Sohn K-H, Park I-W, Choi B-W, Chung DH, et al. Cigarette smoke aggravates asthma by inducing memory-like type 3 innate lymphoid cells. Nat Commun. 2022;13:3852. https:\/\/doi.org\/10.1038\/s41467-022-31491-1.","journal-title":"Nat Commun"},{"key":"1265_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-023-02395-5","volume":"24","author":"LX He","year":"2023","unstructured":"He LX, Yang L, Liu T, Li YN, Huang TX, Zhang LL, et al. Group 3 innate lymphoid cells secret neutrophil chemoattractants and are insensitive to glucocorticoid via aberrant GR phosphorylation. Respir Res. 2023;24:90. https:\/\/doi.org\/10.1186\/s12931-023-02395-5.","journal-title":"Respir Res"},{"key":"1265_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.974066","volume":"13","author":"W Luo","year":"2022","unstructured":"Luo W, Hu J, Xu W, Dong J. Distinct spatial and temporal roles for Th1, Th2, and Th17 cells in asthma. Front Immunol. 2022;13:974066. https:\/\/doi.org\/10.3389\/fimmu.2022.974066.","journal-title":"Front Immunol"},{"key":"1265_CR100","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12325-019-01191-2","volume":"37","author":"DJ Jackson","year":"2020","unstructured":"Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E. Ability of serum IgE concentration to predict exacerbation risk and benralizumab efficacy for patients with severe eosinophilic asthma. Adv Ther. 2020;37:718\u201329. https:\/\/doi.org\/10.1007\/s12325-019-01191-2.","journal-title":"Adv Ther"},{"key":"1265_CR101","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12016-022-08955-9","volume":"63","author":"Y Li","year":"2022","unstructured":"Li Y, Leung PSC, Gershwin ME, Song J. New mechanistic advances in Fc\u03b5RI-mast cell\u2013mediated allergic signaling. Clin Rev Allergy Immunol. 2022;63:431\u201346. https:\/\/doi.org\/10.1007\/s12016-022-08955-9.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1265_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.842500","volume":"13","author":"B Peng","year":"2022","unstructured":"Peng B, Sun L, Zhang M, Yan H, Shi G, Xia Z, et al. Role of IL-25 on eosinophils in the initiation of Th2 responses in allergic asthma. Front Immunol. 2022;13:842500. https:\/\/doi.org\/10.3389\/fimmu.2022.842500.","journal-title":"Front Immunol"},{"key":"1265_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010003","volume":"23","author":"M-L Tsai","year":"2021","unstructured":"Tsai M-L, Tsai Y-G, Lin Y-C, Hsu Y-L, Chen Y-T, Tsai M-K, et al. IL-25 induced ROS-mediated M2 macrophage polarization via AMPK-associated mitophagy. IJMS. 2021;23:3. https:\/\/doi.org\/10.3390\/ijms23010003.","journal-title":"IJMS"},{"key":"1265_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103100","volume":"71","author":"M Miao","year":"2024","unstructured":"Miao M, Pan M, Chen X, Shen J, Zhang L, Feng X, et al. IL-13 facilitates ferroptotic death in asthmatic epithelial cells via SOCS1-mediated ubiquitinated degradation of SLC7A11. Redox Biol. 2024;71:103100. https:\/\/doi.org\/10.1016\/j.redox.2024.103100.","journal-title":"Redox Biol"},{"key":"1265_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22834-5","volume":"12","author":"E Conde","year":"2021","unstructured":"Conde E, Bertrand R, Balbino B, Bonnefoy J, Stackowicz J, Caillot N, et al. Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice. Nat Commun. 2021;12:2574. https:\/\/doi.org\/10.1038\/s41467-021-22834-5.","journal-title":"Nat Commun"},{"key":"1265_CR106","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.3390\/cells10102615","volume":"10","author":"S Esnault","year":"2021","unstructured":"Esnault S, Johansson MW, Mathur SK. Eosinophils, beyond IL-5. Cells. 2021;10:2615. https:\/\/doi.org\/10.3390\/cells10102615.","journal-title":"Cells"},{"key":"1265_CR107","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-022-01976-2","volume":"22","author":"Y Li","year":"2022","unstructured":"Li Y, Lan F, Yang Y, Xu Y, Chen Y, Qin X, et al. The absence of IL-9 reduces allergic airway inflammation by reducing ILC2, Th2 and mast cells in murine model of asthma. BMC Pulm Med. 2022;22:180. https:\/\/doi.org\/10.1186\/s12890-022-01976-2.","journal-title":"BMC Pulm Med"},{"key":"1265_CR108","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/COPD.S233461","volume":"15","author":"Q Ding","year":"2020","unstructured":"Ding Q, Sun S, Zhang Y, Tang P, Lv C, Ma H, et al. Serum IL-8 and VEGFA are two promising diagnostic biomarkers of asthma-COPD overlap syndrome. COPD. 2020;15:357\u201365. https:\/\/doi.org\/10.2147\/COPD.S233461.","journal-title":"COPD"},{"key":"1265_CR109","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jaci.2023.02.028","volume":"152","author":"M Gauthier","year":"2023","unstructured":"Gauthier M, Kale SL, Oriss TB, Gorry M, Ramonell RP, Dalton K, et al. CCL5 is a potential bridge between type 1 and type 2 inflammation in asthma. J Allergy Clin Immunol. 2023;152:94\u2013106.e12. https:\/\/doi.org\/10.1016\/j.jaci.2023.02.028.","journal-title":"J Allergy Clin Immunol"},{"key":"1265_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102970","volume":"68","author":"J Song","year":"2023","unstructured":"Song J, Zhang H, Tong Y, Wang Y, Xiang Q, Dai H, et al. Molecular mechanism of interleukin-17A regulating airway epithelial cell ferroptosis based on allergic asthma airway inflammation. Redox Biol. 2023;68:102970. https:\/\/doi.org\/10.1016\/j.redox.2023.102970.","journal-title":"Redox Biol"},{"key":"1265_CR111","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jaci.2024.07.024","volume":"154","author":"F Bick","year":"2024","unstructured":"Bick F, Brenis G\u00f3mez CM, Lammens I, Van Moorleghem J, De Wolf C, Dupont S, et al. IL-2 family cytokines IL-9 and IL-21 differentially regulate innate and adaptive type 2 immunity in asthma. J Allergy Clin Immunol. 2024;154:1129\u201345. https:\/\/doi.org\/10.1016\/j.jaci.2024.07.024.","journal-title":"J Allergy Clin Immunol"},{"key":"1265_CR112","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaci.2021.04.010","volume":"149","author":"YE Badi","year":"2022","unstructured":"Badi YE, Pavel AB, Pavlidis S, Riley JH, Bates S, Kermani NZ, et al. Mapping atopic dermatitis and anti\u2013IL-22 response signatures to type 2\u2013low severe neutrophilic asthma. J Allergy Clin Immunol. 2022;149:89\u2013101. https:\/\/doi.org\/10.1016\/j.jaci.2021.04.010.","journal-title":"J Allergy Clin Immunol"},{"key":"1265_CR113","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.alit.2021.07.004","volume":"71","author":"S Chen","year":"2022","unstructured":"Chen S, Chen Z, Deng Y, Zha S, Yu L, Li D, et al. Prevention of IL-6 signaling ameliorates toluene diisocyanate-induced steroid-resistant asthma. Allergol Int. 2022;71:73\u201382. https:\/\/doi.org\/10.1016\/j.alit.2021.07.004.","journal-title":"Allergol Int"},{"key":"1265_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66617-2","volume":"10","author":"N Al-Azzam","year":"2020","unstructured":"Al-Azzam N, Teegala LR, Pokhrel S, Ghebreigziabher S, Chachkovskyy T, Thodeti S, et al. Transient receptor potential vanilloid channel regulates fibroblast differentiation and airway remodeling by modulating redox signals through NADPH oxidase 4. Sci Rep. 2020;10:9827. https:\/\/doi.org\/10.1038\/s41598-020-66617-2.","journal-title":"Sci Rep"},{"key":"1265_CR115","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.alit.2019.11.002","volume":"69","author":"Y Yun","year":"2020","unstructured":"Yun Y, Kanda A, Kobayashi Y, Van Bui D, Suzuki K, Sawada S, et al. Increased CD69 expression on activated eosinophils in eosinophilic chronic rhinosinusitis correlates with clinical findings. Allergol Int. 2020;69:232\u20138. https:\/\/doi.org\/10.1016\/j.alit.2019.11.002.","journal-title":"Allergol Int"},{"key":"1265_CR116","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00827-2019","volume":"55","author":"Y-M Kim","year":"2020","unstructured":"Kim Y-M, Kim H, Lee S, Kim S, Lee J-U, Choi Y, et al. Airway G-CSF identifies neutrophilic inflammation and contributes to asthma progression. Eur Respir J. 2020;55:1900827. https:\/\/doi.org\/10.1183\/13993003.00827-2019.","journal-title":"Eur Respir J"},{"key":"1265_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087029","volume":"24","author":"S Rojo-Tolosa","year":"2023","unstructured":"Rojo-Tolosa S, S\u00e1nchez-Mart\u00ednez JA, Pineda-Lancheros LE, G\u00e1lvez-Navas JM, Gonz\u00e1lez-Guti\u00e9rrez MV, Jim\u00e9nez-G\u00e1lvez G, et al. Influence of genetics on the response to omalizumab in patients with severe uncontrolled asthma with an allergic phenotype. IJMS. 2023;24:7029. https:\/\/doi.org\/10.3390\/ijms24087029.","journal-title":"IJMS"},{"key":"1265_CR118","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5578\/tt.20239904","volume":"71","author":"D Ediger","year":"2023","unstructured":"Ediger D, G\u00fcnayd\u0131n FE, Erbay M, Pekbak G. Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab. Tuberk Toraks. 2023;71:24\u201333. https:\/\/doi.org\/10.5578\/tt.20239904.","journal-title":"Tuberk Toraks"},{"key":"1265_CR119","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.resinv.2025.05.003","volume":"63","author":"E Tsuboi","year":"2025","unstructured":"Tsuboi E, Aoki H, Aizawa K, Komatsubara M, Howarth P. Long-term safety and effectiveness of mepolizumab for patients with bronchial asthma in routine clinical practice in Japan \u2014 final report of special drug use investigation. Respiratory Invest. 2025;63:651\u20139. https:\/\/doi.org\/10.1016\/j.resinv.2025.05.003.","journal-title":"Respiratory Invest"},{"key":"1265_CR120","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","volume":"81","author":"C Domingo Ribas","year":"2021","unstructured":"Domingo Ribas C, Carrillo D\u00edaz T, Blanco Aparicio M, Mart\u00ednez Morag\u00f3n E, Banas Conejero D, S\u00e1nchez Herrero MG, et al. Real world effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study. Drugs. 2021;81:1763\u201374. https:\/\/doi.org\/10.1007\/s40265-021-01597-9.","journal-title":"Drugs"},{"key":"1265_CR121","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/j.jaip.2022.04.014","volume":"10","author":"S Hashimoto","year":"2022","unstructured":"Hashimoto S, Kroes JA, Eger KA, Mau Asam PF, Hofstee HB, Bendien SA, et al. Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma \u2013 first initiators and switchers. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10:2099\u20132108.e6. https:\/\/doi.org\/10.1016\/j.jaip.2022.04.014.","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"key":"1265_CR122","doi-asserted-by":"publisher","first-page":"e0248305","DOI":"10.1371\/journal.pone.0248305","volume":"16","author":"H Yamada","year":"2021","unstructured":"Yamada H, Nakajima M, Matsuyama M, Morishima Y, Arai N, Hida N et al. S <>Loukides editor 2021 Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma. PLoS ONE 16 e0248305 https:\/\/doi.org\/10.1371\/journal.pone.0248305.","journal-title":"PLoS ONE"},{"key":"1265_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110444","volume":"129","author":"C Pelaia","year":"2020","unstructured":"Pelaia C, Busceti MT, Crimi C, Carpagnano GE, Lombardo N, Terracciano R, et al. Real-life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomed Pharmacother. 2020;129:110444. https:\/\/doi.org\/10.1016\/j.biopha.2020.110444.","journal-title":"Biomed Pharmacother"},{"key":"1265_CR124","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jaci.2024.11.024","volume":"155","author":"KE Stewart","year":"2025","unstructured":"Stewart KE, RuiWen Kuo C, Chan R, Lipworth BJ. Effects of dupilumab on mannitol airway hyperresponsiveness in uncontrolled severe asthma. J Allergy Clin Immunol. 2025;155:834\u2013842.e6. https:\/\/doi.org\/10.1016\/j.jaci.2024.11.024.","journal-title":"J Allergy Clin Immunol"},{"key":"1265_CR125","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jaip.2023.12.006","volume":"12","author":"LB Bacharier","year":"2024","unstructured":"Bacharier LB, Guilbert TW, Katelaris CH, Deschildre A, Phipatanakul W, Liu D, et al. Dupilumab improves lung function parameters in pediatric type 2 asthma: VOYAGE study. The Journal of Allergy and Clinical Immunology: In Practice. 2024;12:948\u201359. https:\/\/doi.org\/10.1016\/j.jaip.2023.12.006.","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"key":"1265_CR126","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00558-2023","volume":"62","author":"AG Fiocchi","year":"2023","unstructured":"Fiocchi AG, Phipatanakul W, Zeiger RS, Durrani SR, Cole J, Msihid J, et al. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study. Eur Respir J. 2023;62:2300558. https:\/\/doi.org\/10.1183\/13993003.00558-2023.","journal-title":"Eur Respir J"},{"key":"1265_CR127","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/02770903.2022.2115927","volume":"60","author":"JF Maspero","year":"2023","unstructured":"Maspero JF, Cardona G, Schonffeldt P, Tolcachier A, Gonz\u00e1lez-Diaz SN, Ya\u00f1ez A, et al. Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study. J Asthma. 2023;60:981\u201390. https:\/\/doi.org\/10.1080\/02770903.2022.2115927.","journal-title":"J Asthma"},{"key":"1265_CR128","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1016\/j.jaip.2021.07.045","volume":"9","author":"J Corren","year":"2021","unstructured":"Corren J, Ambrose CS, Sa\u0142apa K, Roseti SL, Griffiths JM, Parnes JR, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9:4334\u20134342.e6. https:\/\/doi.org\/10.1016\/j.jaip.2021.07.045.","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"key":"1265_CR129","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00316-2024","volume":"64","author":"ME Wechsler","year":"2024","unstructured":"Wechsler ME, Brusselle G, Virchow JC, Bourdin A, Kostikas K, Llanos J-P, et al. Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies. Eur Respir J. 2024;64:2400316. https:\/\/doi.org\/10.1183\/13993003.00316-2024.","journal-title":"Eur Respir J"},{"key":"1265_CR130","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1007\/s12325-023-02659-y","volume":"40","author":"A Menzies-Gow","year":"2023","unstructured":"Menzies-Gow A, Ambrose CS, Colice G, Hunter G, Cook B, Molfino NA, et al. Effect of tezepelumab on lung function in patients with severe, uncontrolled asthma in the phase 3 NAVIGATOR study. Adv Ther. 2023;40:4957\u201371. https:\/\/doi.org\/10.1007\/s12325-023-02659-y.","journal-title":"Adv Ther"},{"key":"1265_CR131","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.anai.2020.10.008","volume":"126","author":"J Corren","year":"2021","unstructured":"Corren J, Garcia Gil E, Griffiths JM, Parnes JR, Van Der Merwe R, Sa\u0142apa K, et al. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Ann Allergy Asthma Immunol. 2021;126:187\u201393. https:\/\/doi.org\/10.1016\/j.anai.2020.10.008.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1265_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01526-6","volume":"21","author":"A Menzies-Gow","year":"2020","unstructured":"Menzies-Gow A, Colice G, Griffiths JM, Almqvist G, Ponnarambil S, Kaur P, et al. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020;21:266. https:\/\/doi.org\/10.1186\/s12931-020-01526-6.","journal-title":"Respir Res"},{"key":"1265_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01503-z","volume":"21","author":"ME Wechsler","year":"2020","unstructured":"Wechsler ME, Colice G, Griffiths JM, Almqvist G, Sk\u00e4rby T, Piechowiak T, et al. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir Res. 2020;21:264. https:\/\/doi.org\/10.1186\/s12931-020-01503-z.","journal-title":"Respir Res"},{"key":"1265_CR134","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1084\/jem.20051506","volume":"202","author":"IP Lewkowich","year":"2005","unstructured":"Lewkowich IP, Herman NS, Schleifer KW, Dance MP, Chen BL, Dienger KM, et al. CD4\u2009+\u2009CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J Exp Med. 2005;202:1549\u201361. https:\/\/doi.org\/10.1084\/jem.20051506.","journal-title":"J Exp Med"},{"key":"1265_CR135","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1634","volume":"12","author":"TWM Keil","year":"2020","unstructured":"Keil TWM, Baldassi D, Merkel OM. T-cell targeted pulmonary siRNA delivery for the treatment of asthma. WIREs Nanomed Nanobiotechnol. 2020;12:e1634. https:\/\/doi.org\/10.1002\/wnan.1634.","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"1265_CR136","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/ph15030321","volume":"15","author":"MH Alyami","year":"2022","unstructured":"Alyami MH, Dahmash EZ, Ali DK, Alyami HS, AbdulKarim H, Alsudir SA. Novel fluticasone propionate and salmeterol fixed-dose combination nano-encapsulated particles using polyamide based on L-lysine. Pharmaceuticals. 2022;15:321. https:\/\/doi.org\/10.3390\/ph15030321.","journal-title":"Pharmaceuticals"},{"key":"1265_CR137","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s13346-021-01102-5","volume":"12","author":"EF Craparo","year":"2022","unstructured":"Craparo EF, Drago SE, Quaglia F, Ungaro F, Cavallaro G. Development of a novel rapamycin loaded nano- into micro-formulation for treatment of lung inflammation. Drug Deliv Transl Res. 2022;12:1859\u201372. https:\/\/doi.org\/10.1007\/s13346-021-01102-5.","journal-title":"Drug Deliv Transl Res"},{"key":"1265_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.onano.2023.100129","volume":"11","author":"MA Rajizadeh","year":"2023","unstructured":"Rajizadeh MA, Nematollahi MH, Jafari E, Bejeshk MA, Mehrabani M, Razeghinia MS, et al. Niosome nanocarrier enhances the ameliorating effects of myrtenol in the lungs of rats with experimental asthma. Open Nano. 2023;11:100129. https:\/\/doi.org\/10.1016\/j.onano.2023.100129.","journal-title":"Open Nano"},{"key":"1265_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13081300","volume":"13","author":"L Casula","year":"2021","unstructured":"Casula L, Lai F, Pini E, Valenti D, Sinico C, Cardia MC, et al. Pulmonary delivery of curcumin and beclomethasone dipropionate in a multicomponent nanosuspension for the treatment of bronchial asthma. Pharmaceutics. 2021;13:1300. https:\/\/doi.org\/10.3390\/pharmaceutics13081300.","journal-title":"Pharmaceutics"},{"key":"1265_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03827-2","volume":"11","author":"L Kaye","year":"2021","unstructured":"Kaye L, Gondalia R, Thompson A, Stempel DA, Barrett MA. The relationship between objective app engagement and medication adherence in asthma and COPD: a retrospective analysis. Sci Rep. 2021;11:24343. https:\/\/doi.org\/10.1038\/s41598-021-03827-2.","journal-title":"Sci Rep"},{"key":"1265_CR141","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.jaip.2019.08.034","volume":"7","author":"BE Himes","year":"2019","unstructured":"Himes BE, Leszinsky L, Walsh R, Hepner H, Wu AC. Mobile health and inhaler-based monitoring devices for asthma management. J Allergy Clin Immunol Pract. 2019;7:2535\u201343. https:\/\/doi.org\/10.1016\/j.jaip.2019.08.034.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1265_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-024-00382-x","volume":"34","author":"ML Levy","year":"2024","unstructured":"Levy ML, Kocks JWH, Bosnic-Anticevich S, Safioti G, Reich M, Depietro M, et al. Uncovering patterns of inhaler technique and reliever use: the value of objective, personalized data from a digital inhaler. NPJ Prim Care Respir Med. 2024;34:23. https:\/\/doi.org\/10.1038\/s41533-024-00382-x.","journal-title":"NPJ Prim Care Respir Med"},{"key":"1265_CR143","doi-asserted-by":"publisher","DOI":"10.3390\/s24216848","volume":"24","author":"I Mysovskikh","year":"2024","unstructured":"Mysovskikh I, Legg M, Demidenko S. Flowrate sensing and measurement in portable smart inhalers. Sensors. 2024;24:6848. https:\/\/doi.org\/10.3390\/s24216848.","journal-title":"Sensors"},{"key":"1265_CR144","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2023-002275","volume":"11","author":"AHY Chan","year":"2024","unstructured":"Chan AHY, Te Ao B, Baggott C, Cavadino A, Eikholt AA, Harwood M, et al. DIGIPREDICT: physiological, behavioural and environmental predictors of asthma attacks\u2014a prospective observational study using digital markers and artificial intelligence\u2014study protocol. BMJ Open Respir Res. 2024;11:e002275. https:\/\/doi.org\/10.1136\/bmjresp-2023-002275.","journal-title":"BMJ Open Respir Res"},{"key":"1265_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2021.604475","volume":"3","author":"V Brennan","year":"2021","unstructured":"Brennan V, Mulvey C, Greene G, Hale EM, Costello RW. A clinical perspective on the role of electronic devices in monitoring and promoting adherence in airways disease. Front Med Technol. 2021;3:604475. https:\/\/doi.org\/10.3389\/fmedt.2021.604475.","journal-title":"Front Med Technol"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01265-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-026-01265-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01265-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:29:08Z","timestamp":1781638148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-026-01265-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":145,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1007\/s11882-026-01265-6","relation":{},"ISSN":["1534-6315"],"issn-type":[{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a review and does not report any original data involving human participants or animals. Therefore, ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All authors have reviewed and approved the final version of the manuscript and consent to its submission for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}